Investor Presentaiton
Major R&D Milestones (5DXd-ADCS 2)
Project
Target Indication
[phase, study name]
NSCLC
• 2/3L [Ph3, TROPION-Lung01]
Dato-DXd
BC
• HR+ and HER2 low or negative BC, 2/3L
[Ph3, TROPION-Breast01]
•
TNBC, 1L
HER3-DXd
NSCLC
[Ph3, TROPION-Breast02]
• EGFR mutated, 2L
[Ph3, HERTHENA-Lung02]
DS-7300
(I-DXd)
SCLC
.
2L [Dose optimization, Ph2]
As of Jul 2023
FY2023
FY2024
H1
H2
•
TLR obtained
• TLR anticipated
TLR anticipated
TLR anticipated
.
⚫ TLR anticipated
Daiichi-Sankyo
Bold: update from FY2022 Q4
BC: breast cancer, HR: hormone receptor, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TLR: top line results, TNBC: triple-negative breast cancer
Timeline indicated is based on the current forecast and subject to change
33View entire presentation